
Eli Lilly's tirzepatide, presumably the biggest contender for Novo Nordisk's newest generation of diabetes drugs, has taken a pivotal step on the pathway toward future market launches.
During an investment community meeting on Wednesday, Eli Lilly announced that it has submitted the type 2 diabetes drug for marketing approvals in the EU, US, Japan and an additional six other international markets.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app